Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Scientific and clinical data on BriaCell’s (BCT) lead candidate, Bria-IMT, was recently published on-line
  • The publication highlighted the approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action
  • BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for cancer management
  • BriCell Therapeutics (BCT) opened trading at C$7.25 a share

Scientific and clinical data on BriaCell’s (BCT) lead candidate, Bria-IMT was recently published on-line in Recent Patents on Anti-Cancer Drug Discovery.

The publication focused on research in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery and highlighted the approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action.

BriaCell’s President and CEO, Dr. William V. Williams, MD, explained that the paper highlights the company’s findings of rapid tumour shrinkage in multiple anatomic locations, including difficult-to-treat sites like the brain.

“We are even more excited to see the potential positive effect on survival in these patients. Having these scientific and clinical findings published in such a highly regarded journal is a significant achievement for BriaCell. The results support our approach for selecting patients most likely to benefit from our immunotherapy. This undergirds our current strategy of building a pipeline of off-the-shelf personalized immunotherapies as potentially safe and effective treatments for advanced breast cancer and other cancers.”

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for cancer management.

BriCell Therapeutics (BCT) opened trading at C$7.25 a share.

More From The Market Herald
Small Pharma - CEO, George Tziras.

" Small Pharma (TSXV:DMT) announces NCIB

Small Pharma (DMT) has received TSXV approval for a normal course issuer bid.
Spectral Medical Inc. - CMO, Dr. John Kellum

" Spectral (TSX:EDT) gets FDA approval for Tigris trial

Spectral Medical (EDT) announced that the U.S. Food and Drug Administration (FDA) has approved ten new clinical trial sites for the Tigris trial.

" Diagnos (TSXV:ADK) receives approval for its AI enabled Pathology Detection Systems

Diagnos (ADK) has received approval from the Costa Rican regulatory agency for its Artificial Intelligence (AI) enabled Pathology Detection Systems.

" BioHarvest (CSE:BHSC) launches first major U.S marketing campaign

BioHarvest Sciences (BHSC) has announced the first multimedia campaign for VINIA in the USA, Phase 1.